ZA201006378B - Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof - Google Patents
Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof Download PDFInfo
- Publication number
- ZA201006378B ZA201006378B ZA2010/06378A ZA201006378A ZA201006378B ZA 201006378 B ZA201006378 B ZA 201006378B ZA 2010/06378 A ZA2010/06378 A ZA 2010/06378A ZA 201006378 A ZA201006378 A ZA 201006378A ZA 201006378 B ZA201006378 B ZA 201006378B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- compound
- alkyl
- group
- aryl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 13
- 150000003839 salts Chemical class 0.000 title description 6
- 239000000543 intermediate Substances 0.000 title description 5
- 238000002360 preparation method Methods 0.000 title description 4
- SSKYNJZREFFALT-ZLUOBGJFSA-N (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid Chemical class C1N[C@H](C(O)=O)[C@H]2C(C)(C)[C@H]21 SSKYNJZREFFALT-ZLUOBGJFSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 125000000217 alkyl group Chemical group 0.000 description 24
- -1 methyl ester hydrochloride Chemical class 0.000 description 19
- 125000003118 aryl group Chemical group 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 125000000753 cycloalkyl group Chemical group 0.000 description 12
- 125000003710 aryl alkyl group Chemical group 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 125000002877 alkyl aryl group Chemical group 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005513 benzoazaindolyl group Chemical group 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 125000005368 heteroarylthio group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/20—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47951603P | 2003-06-17 | 2003-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201006378B true ZA201006378B (en) | 2011-05-25 |
Family
ID=33539184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2010/06378A ZA201006378B (en) | 2003-06-17 | 2010-09-06 | Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7309717B2 (enExample) |
| EP (1) | EP1633711B1 (enExample) |
| JP (1) | JP4825129B2 (enExample) |
| CN (2) | CN101823965B (enExample) |
| AT (1) | ATE489365T1 (enExample) |
| CA (1) | CA2526635C (enExample) |
| DE (1) | DE602004030239D1 (enExample) |
| ES (1) | ES2354817T3 (enExample) |
| MX (1) | MXPA05013752A (enExample) |
| SG (1) | SG180022A1 (enExample) |
| WO (1) | WO2004113295A1 (enExample) |
| ZA (1) | ZA201006378B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR049635A1 (es) * | 2004-05-06 | 2006-08-23 | Schering Corp | (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c |
| US20060276407A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
| US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
| EP1898941A2 (en) * | 2005-06-02 | 2008-03-19 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
| US20060281689A1 (en) * | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
| US8119602B2 (en) | 2005-06-02 | 2012-02-21 | Schering Corporation | Administration of HCV protease inhibitors in combination with food to improve bioavailability |
| ES2572980T3 (es) * | 2005-06-02 | 2016-06-03 | Merck Sharp & Dohme Corp. | Combinación de inhibidores de la proteasa del VHC con un tensioactivo |
| WO2006130666A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
| WO2006130687A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor |
| WO2006130552A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| AR056805A1 (es) * | 2005-11-14 | 2007-10-24 | Schering Corp | Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados |
| WO2007075790A1 (en) * | 2005-12-22 | 2007-07-05 | Schering Corporation | Process for the preparation of 6, 6-dimethyl-3-azabicyclo-[3.1.0]-hexane compounds and enantiomeric salts thereof |
| WO2007074391A2 (en) * | 2005-12-28 | 2007-07-05 | Bakulesh Mafatlal Khamar | Preparation of a key intermediate in the synthesis of rosuvastatin |
| KR101059593B1 (ko) | 2006-04-11 | 2011-08-25 | 노파르티스 아게 | Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도 |
| WO2007122744A1 (ja) | 2006-04-17 | 2007-11-01 | Sumitomo Chemical Company, Limited | 多環式プロリン誘導体又はその酸付加塩の製造方法 |
| CN101415676A (zh) | 2006-04-17 | 2009-04-22 | 住友化学株式会社 | N-叔丁氧基羰基-2-吡咯烷酮类及其制造方法 |
| JP5272324B2 (ja) * | 2006-04-17 | 2013-08-28 | 住友化学株式会社 | Ｎ−ｔｅｒｔ−ブトキシカルボニル−２−ピロリジノン類およびその製造方法 |
| JP5272325B2 (ja) * | 2006-04-17 | 2013-08-28 | 住友化学株式会社 | 多環式プロリン誘導体またはその酸付加塩の製造方法 |
| SG160363A1 (en) | 2006-04-17 | 2010-04-29 | Sumitomo Chemical Company Limt | Ester of cyclic carboxylic acid |
| JP2010513492A (ja) * | 2006-12-19 | 2010-04-30 | シェーリング コーポレイション | ３−（アミノ）−３−（シクロブチルメチル）−２−（ヒドロキシ）−プロピオンアミド塩酸塩の調製 |
| JP5095824B2 (ja) | 2007-10-10 | 2012-12-12 | ノバルティス アーゲー | スピロピロリジン類およびｈｃｖおよびｈｉｖ感染に対するその使用 |
| WO2009073380A1 (en) * | 2007-11-28 | 2009-06-11 | Schering Corporation | Dehydrohalogenation process for the preparation of intermediates useful in providing 6,6-dimethyl-3-azabicyclo-[3.1.0]-hexane compounds |
| US20110137046A1 (en) * | 2008-06-05 | 2011-06-09 | Fen-Er Chen | Preparation method of (4s,5r)-semiester |
| CN102816106A (zh) | 2008-06-24 | 2012-12-12 | 默沙东公司 | 用于制备基本上立体异构纯的稠合二环脯氨酸化合物的生物催化方法 |
| US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| JP5613168B2 (ja) * | 2008-11-17 | 2014-10-22 | アナディス ファーマシューティカルズ インク | デオキシリボフラノース化合物の製造方法 |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| CN101863866B (zh) * | 2009-04-16 | 2012-07-04 | 上海联友制药技术有限公司 | 3,3-二甲基环丙烷-1,2-二甲酸酐的合成方法 |
| WO2011014494A1 (en) | 2009-07-29 | 2011-02-03 | Schering Corporation | ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF β-AMINO-α- HYDROXY AMIDES |
| CN102070575B (zh) * | 2010-12-28 | 2012-10-17 | 上海北卡医药技术有限公司 | 卡隆酸酐的合成方法 |
| CN102127040B (zh) * | 2010-12-30 | 2013-05-01 | 西安彩晶光电科技股份有限公司 | 6,6-二甲基-3-氧杂双环[3.1.0]己烷-2,4-二酮的制备方法 |
| FR2972453B1 (fr) * | 2011-03-09 | 2013-11-29 | Minakem | Nouveau procede de synthese du (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate de methyle ou de l'un de ses sels |
| JP2013010738A (ja) * | 2011-05-31 | 2013-01-17 | Sumitomo Chemical Co Ltd | エステル化合物の製造方法 |
| JP2013010732A (ja) * | 2011-06-03 | 2013-01-17 | Sumitomo Chemical Co Ltd | プロリン化合物の製造方法 |
| JP2013010733A (ja) * | 2011-06-03 | 2013-01-17 | Sumitomo Chemical Co Ltd | ヘミアミナール化合物の製造方法及びシアノアミン化合物の製造方法 |
| JP2013010734A (ja) * | 2011-06-03 | 2013-01-17 | Sumitomo Chemical Co Ltd | Ｎ−置換ラクタム化合物の製造方法 |
| WO2013178682A2 (en) | 2012-05-30 | 2013-12-05 | Chemo Ibérica, S.A. | Multicomponent process for the preparation of bicyclic compounds |
| CN103435532B (zh) * | 2013-09-02 | 2015-07-08 | 苏州永健生物医药有限公司 | 波普瑞韦中间体的合成方法 |
| CN104151279A (zh) * | 2014-08-26 | 2014-11-19 | 广西梧松林化集团有限公司 | 卡龙酸酐的合成方法 |
| CN114539125B (zh) * | 2022-03-07 | 2024-02-09 | 杭州国瑞生物科技有限公司 | 一种帕西洛韦中间体的合成方法 |
| CN114478690B (zh) * | 2022-03-08 | 2024-01-02 | 新发药业有限公司 | 一种6,6-二甲基-3-氮杂双环[3.1.0]己烷衍生物的制备方法 |
| WO2023175526A1 (en) * | 2022-03-16 | 2023-09-21 | Laurus Labs Limited | Process for preparation of azabicyclo [3.1.0] hexane intermediates |
| CN114605309B (zh) * | 2022-03-23 | 2023-07-21 | 浙江新和成股份有限公司 | 一种氮杂双环衍生物的合成方法 |
| CN114989067B (zh) * | 2022-07-18 | 2022-10-28 | 苏州奥普拓新材料有限公司 | 一种帕罗韦德中间体的合成方法 |
| CN115947679B (zh) * | 2022-12-16 | 2024-06-07 | 杭州澳赛诺生物科技有限公司 | 一种6,6-二甲基-3-杂氮-双环[3.1.0]己烷-2-羧酸甲酯的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2376120A1 (fr) * | 1976-12-30 | 1978-07-28 | Roussel Uclaf | Procede de preparation d'esters d'alcoyle inferieur d'acides cis ou trans 3-formyl cyclopropane 1-carboxyliques 2,2-disubstitues racemiques |
| CA1117127A (en) * | 1978-06-27 | 1982-01-26 | Janet A. Day | Derivatives of 3-azabicyclo(3.1.0)hexane and a process for their preparation |
| CA1117128A (en) * | 1978-10-27 | 1982-01-26 | Derek A. Wood | 2-cyano-3-azabicyclo(3.1.0)hexane |
| SI1385870T1 (sl) | 2000-07-21 | 2010-08-31 | Schering Corp | Peptidi kot NS3-serin proteazni inhibitorji virusa hepatitisa C |
| US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| IL144815A (en) * | 2000-08-11 | 2005-07-25 | Sumitomo Chemical Co | Process for producing carbonyl or hydroxy compound |
-
2004
- 2004-06-15 SG SG2010048015A patent/SG180022A1/en unknown
- 2004-06-15 JP JP2006517302A patent/JP4825129B2/ja not_active Expired - Fee Related
- 2004-06-15 CA CA2526635A patent/CA2526635C/en not_active Expired - Fee Related
- 2004-06-15 US US10/867,602 patent/US7309717B2/en not_active Expired - Fee Related
- 2004-06-15 WO PCT/US2004/019135 patent/WO2004113295A1/en not_active Ceased
- 2004-06-15 DE DE602004030239T patent/DE602004030239D1/de not_active Expired - Lifetime
- 2004-06-15 MX MXPA05013752A patent/MXPA05013752A/es active IP Right Grant
- 2004-06-15 CN CN2010101632513A patent/CN101823965B/zh not_active Expired - Fee Related
- 2004-06-15 CN CN2004800166393A patent/CN1805931B/zh not_active Expired - Fee Related
- 2004-06-15 EP EP04776626A patent/EP1633711B1/en not_active Expired - Lifetime
- 2004-06-15 ES ES04776626T patent/ES2354817T3/es not_active Expired - Lifetime
- 2004-06-15 AT AT04776626T patent/ATE489365T1/de active
-
2007
- 2007-11-06 US US11/982,875 patent/US7569705B2/en not_active Expired - Fee Related
-
2009
- 2009-06-15 US US12/484,461 patent/US7728165B2/en not_active Expired - Fee Related
-
2010
- 2010-09-06 ZA ZA2010/06378A patent/ZA201006378B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7728165B2 (en) | 2010-06-01 |
| US20050059648A1 (en) | 2005-03-17 |
| CN1805931A (zh) | 2006-07-19 |
| MXPA05013752A (es) | 2006-03-08 |
| CN101823965B (zh) | 2012-12-19 |
| EP1633711A1 (en) | 2006-03-15 |
| EP1633711B1 (en) | 2010-11-24 |
| HK1081199A1 (en) | 2006-05-12 |
| JP4825129B2 (ja) | 2011-11-30 |
| CA2526635C (en) | 2012-06-05 |
| WO2004113295A1 (en) | 2004-12-29 |
| ES2354817T3 (es) | 2011-03-18 |
| CN1805931B (zh) | 2010-06-23 |
| US7309717B2 (en) | 2007-12-18 |
| CA2526635A1 (en) | 2004-12-29 |
| US20080114179A1 (en) | 2008-05-15 |
| SG180022A1 (en) | 2012-05-30 |
| US20090247784A1 (en) | 2009-10-01 |
| DE602004030239D1 (de) | 2011-01-05 |
| CN101823965A (zh) | 2010-09-08 |
| JP2007520434A (ja) | 2007-07-26 |
| ATE489365T1 (de) | 2010-12-15 |
| US7569705B2 (en) | 2009-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201006378B (en) | Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof | |
| EP2892880B1 (en) | Indole carboxamide derivatives and uses thereof | |
| CN113072497B (zh) | 蛋白酶抑制剂、其制备和用途 | |
| PE20110100A1 (es) | Procedimiento de preparacion de n-[trans-4-[4-(ciclopropilmetil)-1-piperazinil]ciclohexil]-4-[[(7r)-7-etil-5,6,7,8-tetrahidro-5-metil-8-(1-metiletil)-6-oxo-2-pteridinil]amino]-3-metoxi-benzamida | |
| TW200538450A (en) | HCV NS-3 serine protease inhibitors | |
| CN101646671A (zh) | 用作蛋白激酶抑制剂的化合物 | |
| RS20090459A (sr) | Tripeptidi, inhibitori hepatitisa c | |
| CN105517999A (zh) | Ido抑制剂 | |
| JP2011529964A (ja) | 抗菌剤としての尿素誘導体 | |
| TWI635076B (zh) | 吡咯衍生物之製造方法及其中間體 | |
| JP2019525947A (ja) | 化合物 | |
| Lu et al. | Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease | |
| ES2928919T3 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| CN101759601A (zh) | 利用过渡金属配合物制备手性α-非天然氨基酸的方法 | |
| WO2019167085A1 (en) | Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate | |
| CS201033B2 (en) | Method of producing derivatives of n-/3-amino-2-hydroxy-propionyl/-2-amino acetic acid | |
| US20090149657A1 (en) | Process for the synthesis of intermediates of chloramphenicol or its analogues | |
| US6906192B2 (en) | Processes for the preparation of acid derivatives useful as serine protease inhibitors | |
| Beck et al. | New end-on thiolactone scaffold by an isocyanide-based multicomponent reaction | |
| KR20240020712A (ko) | 에난티오퓨어 (s)-메타돈, (r)-메타돈, 라세믹(r,s)-메타돈 및 관련 유사 물질을 합성하는 새로운 방법 | |
| JP2019522651A (ja) | タンパク質キナーゼ阻害剤としての置換されているピロロ［２，３−ｄ］ピリダジン−４−オン及びピラゾロ［３，４−ｄ］ピリダジン−４−オン | |
| RS64934B1 (sr) | Postupak za pripremu ivosideniba i njegovog intermedijera | |
| CN105392891A (zh) | 具有硫醇基的d-型或l-型氨基酸衍生物的制造方法 | |
| CN114920663B (zh) | 一种联苯类奥司他韦衍生物及其制备方法与应用 | |
| CN103814025A (zh) | 可用作胆碱激酶抑制剂的化合物 |